Skip to content

Ultrasound-guided Transversus Abdominis Plane Block With Liposomal Bupivacaine for Pain After Cesarean Section in a prospective, Randomized, Double-Blind, Controlled Trial

Ultrasound-guided Transversus Abdominis Plane Block With Liposomal Bupivacaine for Pain After Cesarean Section in a prospective, Randomized, Double-Blind, Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400085015
Enrollment
Unknown
Registered
2024-05-29
Start date
2024-05-29
Completion date
Unknown
Last updated
2024-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain After Cesarean Section

Interventions

Group B:A bilateral, 2-point classic TAP block with 0.2% bupivacaine hydrochloride(20 mL each side
40 mL total for each)
Group LB:A bilateral, 2-point classic TAP block with LB 266 mg Dilute 20ml (266mg) of bupivacaine liposomes with 20ml of physiological saline to a total volume of 40ml, 20ml per side

Sponsors

Guangzhou Medical University Affiliated Women and Children's Medical Center
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. Women who were scheduled to undergo elective cesarean delivery under spinal anesthesia 2. term gestation (37-42 weeks), 3. American Society of Anesthesiologists physical status of II or III 4. Aged 18 to 45 years; 5. Patients voluntarily participate in the trial and sign an informed consent form 6. Healthy single pregnancy

Exclusion criteria

Exclusion criteria: 1.BMI =40kg/m^2 2.Contraindications to spinal anesthesia 3.Participant received antipsychotic or hypnotic medications, alcohol or drug abuse; 4.Severe pregnancy complications (gestational diabetes, gestational hypertension, heart disease, complete placenta previa, placental abruption, preeclampsia); 5.Allergy, intolerance or contraindication to drugs used in the study; 6.Known fetal abnormalities

Design outcomes

Primary

MeasureTime frame
48h PCA Dosage of opioid drugs in PCA pump within 48 hours;

Secondary

MeasureTime frame
Motor blockade;Side effects;Uterine contraction pain;Wound pain at rest (VAS-R) after cesarean section;Provocative wound while changing position in bed (VAS-P) after cesarean sectionafter cesarean section;First time to use PCA;Time to oral acetaminophen ;Time to out-of-bed activity;Time to first exhaust;Satisfaction with analgesia;

Countries

China

Contacts

Public ContactChen Xi

Guangzhou Medical University Affiliated Women and Children's Medical Cente

877579351@qq.com+86 189 2628 8726

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026